BB-K8: A new aminoglycoside for intravitreal injection in bacterial endophthalmitis.
D000287:Administration, Topical; D000818:Animals; D001082:Aqueous Humor / Q000378:metabolism; D001424:Bacterial Infections / Q000188:drug therapy*; D002386:Cataract / Q000139:chemically induced; D003228:Conjunctiva; D004305:Dose-Response Relationship, Drug; D005128:Eye Diseases / Q000188:drug therapy*; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007500:Iritis / Q000139:chemically induced; D007612:Kanamycin / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity; D011552:Pseudomonas Infections / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D011817:Rabbits; D012162:Retinal Degeneration / Q000139:chemically induced / Q000473:pathology; D013997:Time Factors; D014822:Vitreous Body / Q000378:metabolism
D007612:Kanamycin